NASDAQ:PCVX Vaxcyte Q3 2026 Earnings Results & Report $65.68 +4.87 (+8.01%) Closing price 04:00 PM EasternExtended Trading$65.00 -0.68 (-1.04%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Vaxcyte beat analyst earnings expectations in its Q3 2026 results, released November 4, 2026. The company reported EPS of -$1.99 versus the -$2.11 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 4, 2026TimeAfter Market ClosesConference Call4:00 PM ET Vaxcyte EPS ResultsActual EPS-$1.99Consensus EPS -$2.11Beat/MissBeat by +$0.12One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersVaxcyte Revenue ResultsActual RevenueN/AExpected Revenue$12.50 millionBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Vaxcyte Q3 2026 Earnings FAQ Did Vaxcyte beat earnings estimates for Q3 2026? Vaxcyte (NASDAQ:PCVX) reported earnings of -$1.99 per share for Q3 2026, beating the consensus estimate of -$2.11. The report was announced on Wednesday, November 4, 2026. Vaxcyte Earnings HeadlinesVaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update3 hours ago | globenewswire.comVaxcyte (PCVX) Expected to Release Earnings on TuesdayNovember 2 at 2:57 AM | americanbankingnews.comThe most dangerous moment in a financial crisisDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008.November 4 at 1:00 AM | Weiss Ratings (Ad)Vaxcyte: Vaccine Titan In The MakingOctober 19, 2026 | seekingalpha.comShow Me The Money: Vaxcyte Delivers 100%+ Gains As Pneumococcal Vaccine Program AdvancesOctober 16, 2026 | rttnews.comLeerink Partners Reaffirms Their Buy Rating on Vaxcyte (PCVX)October 12, 2026 | theglobeandmail.comSee More Vaxcyte Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vaxcyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vaxcyte and other key companies, straight to your email. Email Address About VaxcyteVaxcyte (NASDAQ:PCVX) (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines designed to protect against serious bacterial diseases. The company is headquartered in San Carlos, California, and uses its proprietary cell-free protein synthesis and conjugation technologies to develop vaccine candidates intended to provide broad and durable immune protection. Vaxcyte’s lead programs target pneumococcal disease, an infection caused by Streptococcus pneumoniae. Its pipeline includes VAX-24, a 24-valent pneumococcal conjugate vaccine candidate, and VAX-31, a broader 31-valent candidate. The company is evaluating these programs for potential use in adults and children. Vaxcyte does not currently have an approved commercial product, and its vaccine candidates remain subject to clinical development and regulatory review. The company was founded in 2013 as SutroVax and adopted the Vaxcyte name in 2020. Its operations and research activities are based primarily in the United States, with clinical development programs conducted across multiple regions as part of international trials. Grant Pickering, Ph.D., serves as Vaxcyte’s chief executive officer.View Vaxcyte ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?Advanced Micro Devices' Q3 Results Answer a Big Question, But Another Remains3 Dividend Increases Above 10%, But Which Offers the Most Income?High Voltage Returns: Talen Energy Powers the Data Center RushBloom Energy: The Off-Grid Answer to AI's Power DrainWhy ExxonMobil and Chevron Reminded Investors to Keep it SimpleEnergy Transfer's Earnings Miss May Be Hiding Its Strongest Advantage Upcoming Earnings Airbnb (11/5/2026)Sony (11/5/2026)Toyota Motor (11/5/2026)Monster Beverage (11/5/2026)Canadian Natural Resources (11/5/2026)ConocoPhillips (11/5/2026)EOG Resources (11/5/2026)Targa Resources (11/5/2026)TC Energy (11/5/2026)Becton, Dickinson and Company (11/5/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
